AstraZeneca's zibotentan fails first Phase III prostate cancer trial
This article was originally published in Scrip
Executive Summary
AstraZeneca is facing more disappointment with its late-stage oncology pipeline after its experimental drug zibotentan failed to show an improvement in overall survival (the primary endpoint) in its first Phase III trial in metastatic castration-resistant prostate cancer (CRPC).